Rapibloc®
300 mg powder for solution for infusion

Now in Europe

 

Active Pharmaceutical Ingredient: 
landiolol hydrochloride

Pharmacotherapeutic group:
Beta-blocking agents, selective

Indication:

  • Landiolol hydrochloride is indicated for supraventricular tachycardia and for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable.
  • Landiolol hydrochloride is also indicated for non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention.
  • Landiolol is not intended for use in chronic settings.


Package size:
One vial of 50 ml contains 300 mg powder for solution for infusion.

Additional dosage options:
Rapibloc® 20 mg/2 ml concentrate for solution for injection (5 ampules per pack)

 

Learn more about how Rapibloc® can support physicians in managing acute atrial fibrillation.

Brand names may vary by country: Rapibloc, Raploc, Landiobloc, Runrapiq